Oral semaglutide, already approved for type 2 diabetes, led to a reduction in CV events in patients with established ...

Learn how chemists have invented a new technology to solve the shortage of GLP-1 medications by improving drug delivery.

The following is a summary of “Optimizing SGLT2 inhibitor and GLP-1 RA prescribing in high-risk patients with diabetes: a ...

The number of Americans taking cutting-edge weight-loss drugs like Ozempic, Wegovy and Zepbound has skyrocketed in recent years, a new study says.

SAN DIEGO, March 23, 2025 — Glucagon-like peptide-1 (GLP-1) receptor agonists are peptide-based therapeutics for treating diabetes and for weight loss. Unfortunately, shortages and high costs have ...

Use of cutting-edge weight-loss drugs like Ozempic and Zepbound has increased dramatically among people with type 1 diabetes, raising safety concerns among experts, a new study says.

Initial reports of increased suicidality in GLP-1 RA users compared with the general population raised concerns about the risk for this rare but serious adverse event, given the rising popularity ...

Glucagon-like peptide-1 (GLP-1) drugs mimic the GLP-1 hormone, which helps control insulin and blood sugar levels, decreases appetite and slows digestion of food. Both diabetes and obesity ...

Please provide your email address to receive an email when new articles are posted on . A review of randomized clinical trials found 33 occurrences of suicide-related behaviors with GLP-1s vs 27 ...

CordenPharma provides large-scale peptide manufacturing for the Dual GLP-1/GIP Receptor Agonist drug substance of VK2735. CordenPharma provides fill-finish for the drug candidate's subcutaneous ...